More than 1 million men will undergo a prostate biopsy this year, but only about one-fifth of those biopsies will result in a prostate cancer diagnosis.
The reason is that the traditional prostate cancer screening test – a blood test to measure prostate specific antigen, or PSA – does not give doctors a complete picture.
A new test developed at the University of Michigan Comprehensive Cancer Center improves upon PSA. It adds two more markers that might indicate prostate cancer. Studies have shown the urine-based test, called Mi-Prostate Score, is far more accurate than PSA alone. Continue reading